MDUMFA II Discussions May Touch On Need For FDA Guidance, Transparency
This article was originally published in The Gray Sheet
Executive Summary
Industry is not satisfied with FDA's current rate of issuing guidances, according to Anthony Blank, Boston Scientific VP-cardiovascular regulatory affairs